Phase I Clinical Trial of Systemically Administered TUSC2(FUS1)-Nanoparticles Mediating Functional Gene Transfer in Humans

BACKGROUND: Tumor suppressor gene TUSC2/FUS1 (TUSC2) is frequently inactivated early in lung cancer development. TUSC2 mediates apoptosis in cancer cells but not normal cells by upregulation of the intrinsic apoptotic pathway. No drug strategies currently exist targeting loss-of–function genetic abn...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Charles, Stewart, David J., Lee, J. Jack, Ji, Lin, Ramesh, Rajagopal, Jayachandran, Gitanjali, Nunez, Maria I., Wistuba, Ignacio I., Erasmus, Jeremy J., Hicks, Marshall E., Grimm, Elizabeth A., Reuben, James M., Baladandayuthapani, Veerabhadran, Templeton, Nancy S., McMannis, John D., Roth, Jack A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3338819/
https://www.ncbi.nlm.nih.gov/pubmed/22558101
http://dx.doi.org/10.1371/journal.pone.0034833

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3338819/
https://www.ncbi.nlm.nih.gov/pubmed/22558101
http://dx.doi.org/10.1371/journal.pone.0034833

Ejemplares similares